Heliyon (Jan 2024)

Global trends in bufalin application research for cancer from 2003 to 2022: A bibliometric and visualised analysis

  • Donghao Tang,
  • Yuejiao Feng,
  • Jiahao Lu,
  • Linlin Jia,
  • Dongxiao Shen,
  • Jing Shang,
  • Teng Chen,
  • Peihao Yin,
  • Jinbao Chen,
  • Jie Wang

Journal volume & issue
Vol. 10, no. 2
p. e24395

Abstract

Read online

Background: Bufalin, the main active ingredient of the traditional Chinese medicine huachansu, is used in the clinical treatment of colorectal cancer and has multiple effects, including the inhibition of migratory invasion, reversal of multi-drug resistance, induction of apoptosis and differentiation, and inhibition of angiogenesis. Methods: We collected relevant articles on bufalin from 2003 to 2022 using the Web Science platform, and analysed the information using VOSviewer, CiteSpace, and Microsoft Excel to categorise and summarise the publications over the past 20 years. Results: We collected 371 papers, with a steady increase in the number of articles published globally. China has the highest number of published articles, whereas Japan has the highest number of citations. Currently, there is considerable enthusiasm for investigating the anti-tumour mechanism of bufalin and optimising drug delivery systems for its administration. Conclusion: For the first time, we present a comprehensive overview of papers published worldwide on bufalin over the past two decades and the progress of its application in tumour therapy. We summarised the key authors, institutions, and countries that have contributed to the field and the potential of bufalin for the treatment of cancer. This will help other researchers obtain an overview of progress in the field, enhance collaboration and knowledge sharing, and promote future research on bufalin.

Keywords